Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) said twice-daily 400 mg oral CK-101 (RX518) led to an objective response rate (ORR) of 75% in eight treatment-naïve patients with EGFR mutation-positive

Read the full 275 word article

User Sign In